Table 1.
Patient characteristics
| Mitiglinide | Glimepiride | |
|---|---|---|
| n (M/F) |
15 (10/5) |
7 (6/1) |
| Age, years |
58.5 ± 11.5 |
65.1 ± 7.5 |
| BMI, kg/m2 |
24.8 ± 4.0 |
26.3 ± 6.2 |
| SBP, mmHg |
137 ± 17 |
132 ± 20 |
| DBP, mmHg |
80 ± 7 |
79 ± 11 |
| Total cholesterol, mmol/L |
5.38 ± 0.98 |
5.43 ± 1.08 |
| (mg/dL) |
(208 ± 38) |
(210 ± 42) |
| Triglycerides, mmol/L |
1.71 ± 1.14 |
1.89 ± 0.74 |
| (mg/dL) |
(152 ± 101) |
(168 ± 66) |
| HDL-C, mmol/L |
1.39 ± 0.38 |
1.37 ± 0.31 |
| (mg/dL) |
(54 ± 15) |
(53 ± 12) |
| Fasting glucose, mmol/L |
6.88 ± 1.27 |
8.16 ± 1.05 |
| (mg/dL) |
(124 ± 23) |
(147 ± 19) |
| 2-h postload glucose, mmol/L |
9.11 ± 1.94 |
11.6 ± 1.77 |
| (mg/dL) |
(164 ± 35) |
(209 ± 32) |
| HbA1c(NGSP),% |
6.80 ± 0.54 |
7.60 ± 0.63 |
| Fasting IRI, pmol/L |
52.7 ± 53.4 |
49.3 ± 36.1 |
| (ng/mL) |
(7.6 ± 7.7) |
(7.1 ± 5.2) |
| HOMA-R |
2.55 ± 3.10 |
2.67 ± 2.09 |
| ISI (Matsuda’s index) |
7.73 ± 3.16 |
7.68 ± 4.69 |
| Insulinogenic index |
0.80 ± 0.61 |
0.42 ± 0.38 |
| CPR, nmol/L |
0.59 ± 0.30 |
0.57 ± 0.17 |
| (ng/mL) |
(1.79 ± 0.93) |
(1.72 ± 0.51) |
| Proinsulin, pmol/L |
4.29 ± 4.16 |
4.77 ± 4.04 |
| PI/I ratio | 0.10 ± 0.11 | 0.19 ± 0.26 |
Data are means ± standard deviation.
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; HbA1c, hemoglobin A1c; NGSP, National Glycohemoglobin Standardization Program; IRI, immunoreactive insulin; HOMA-IR, homeostasis model assessment of insulin resistance; ISI, insulin sensitivity index; CPR, C-peptide immunoreactivity; PI/I ratio, proinsulin/insulin ratio.